Literature DB >> 17537675

Testing the limits of case finding for HIV prevention.

Michael M Cassell1, Alison Surdo.   

Abstract

HIV testing technologies have been available for two decades, but concerns about stigma and discrimination have historically tempered the application of case finding-a cornerstone of public-health practice-to combat the HIV/AIDS pandemic. The recent expansion of access to HIV treatment has resulted in a shift of emphasis from pairing testing with rigorous risk-reduction prevention counselling, to applying testing to find infected individuals, address their care and treatment needs, and prevent them from infecting others. However, the efficacy of case finding for infectious disease prevention is contingent on two basic principles: the ability to identify infected individuals before further transmission occurs, and the availability of effective strategies to prevent such transmission from taking place. Although there is evidence that specific approaches to HIV counselling and testing can support behaviour change, both high infectivity during early HIV infection and specific sexual network structures could combine to substantially limit our ability to identify cases before ongoing transmission occurs. Facilitating the broader adoption of prevention behaviours therefore remains essential to prevent the continued spread of HIV.

Entities:  

Mesh:

Year:  2007        PMID: 17537675     DOI: 10.1016/S1473-3099(07)70114-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  2 in total

1.  Public health. Reassessing HIV prevention.

Authors:  Malcolm Potts; Daniel T Halperin; Douglas Kirby; Ann Swidler; Elliot Marseille; Jeffrey D Klausner; Norman Hearst; Richard G Wamai; James G Kahn; Julia Walsh
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

2.  Exploring the relative costs of contact tracing for increasing HIV case finding in sub-Saharan countries.

Authors:  Benjamin Armbruster; Stéphane Helleringer; Linda Kalilani-Phiri; James Mkandawire; Hans-Peter Kohler
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.